{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:11:31Z","timestamp":1751947891618,"version":"3.41.2"},"posted":{"date-parts":[[2025,4,4]]},"group-title":"In Review","reference-count":59,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,3,20]]},"abstract":"<title>Abstract<\/title>\n        <p>The development of cholinergic neurotransmitter based cognitive enhancers for Alzheimer\u2019s disease and other neuropsychiatric disorders have focused recently on allosteric modulation of specific muscarinic acetylcholine receptor (mAChR) subtypes to reduce dose-limiting side-effects that have been the hallmark of earlier orthosteric mAChR agonists. VU0467319 (VU319) is an investigational positive allosteric modulator of the M<sub>1<\/sub> mAChR. A Phase 1 first-in-human study was conducted assessing safety and brain activity utilizing cognitive tasks and event-related potentials (ERPs) in single-ascending dose and food effect studies. VU319 was given orally to 52 healthy volunteers aged 18\u201355 years. The single ascending dose study tested 40 participants in five dose escalating cohorts (60, 120, 240, 400, 600 mg; 6 VU319\/2 placebo per dose). The food effect study involved 12 participants, 10 VU319 (120 mg)\/2 placebo. Exploratory cognitive and electrophysiological tasks were examined pre-dosing and at 5 hours post-dose. Tolerability was good with no observed dose limiting side effects throughout the full dose range tested. Drug exposure increased with dose in a less than dose-proportional manner with a half-life ranging from 36 to 43 hours. Absorption was increased with food. Exploratory cognitive\/ERP testing showed evidence for drug-induced CNS activity on higher doses of VU319 compared to placebo. Single dose VU319 across five ascending cohorts appeared to have a favorable safety profile and a PK profile consistent with once daily dosing. Target engagement results suggest stimulation of the cholinergic system functioning in healthy adults following a single dose of VU319. These results provide a strong foundation for further studies of positive allosteric modulators of muscarinic M<sub>1<\/sub> receptors for potential cognitive or behavioral benefits.<\/p>","DOI":"10.21203\/rs.3.rs-6271510\/v1","type":"posted-content","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T11:41:03Z","timestamp":1743766863000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer\u2019s disease: A Single Ascending-Dose Study in Healthy Participants"],"prefix":"10.21203","author":[{"given":"Alexander C.","family":"Conley","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra P.","family":"Key","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer U.","family":"Blackford","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason K.","family":"Russell","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, University of Southern California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly M.","family":"Albert","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuewen","family":"Gong","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bubser","sequence":"additional","affiliation":[{"name":"Vanderbilt University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerri M.","family":"Rook","sequence":"additional","affiliation":[{"name":"Vanderbilt University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Jeffrey","family":"Conn","sequence":"additional","affiliation":[{"name":"Vanderbilt University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig W.","family":"Lindsley","sequence":"additional","affiliation":[{"name":"Vanderbilt University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie K.","family":"Jones","sequence":"additional","affiliation":[{"name":"Vanderbilt University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Newhouse","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","first-page":"3","article-title":"Diagnosis and treatment of Alzheimer\u2019s disease","volume":"64","author":"Grossberg GT","year":"2003","unstructured":"Grossberg GT. Diagnosis and treatment of Alzheimer\u2019s disease. J Clin Psychiatry. 2003;64:3\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann GM","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"author":"Hampel H","key":"ref3","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain [Internet]. 2023 Nov 1 [cited 2025 Feb 11];146(11):4414. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10629981\/"},{"author":"Beveridge J","key":"ref4","unstructured":"Beveridge J, Kaniecki E, Naidu A, Silverglate BD, Grossberg G. How promising are the latest monoclonal antibodies targeting amyloid-\u03b2 for the treatment of early Alzheimer\u2019s disease? Expert Opin Emerg Drugs [Internet]. 2024 [cited 2025 Feb 11];29(1):35\u201343. Available from: https:\/\/www.tandfonline.com\/action\/journalInformation?journalCode=iemd20"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pbb.2011.02.022","article-title":"The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation","volume":"99","author":"Dumas JA","year":"2011","unstructured":"Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation. Pharmacol Biochem Behav. 2011;99(2):254\u201361.","journal-title":"Pharmacol Biochem Behav"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus RT","year":"1982","unstructured":"Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408\u201314.","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0301-0082(02)00079-5","article-title":"Alzheimer\u2019s disease and the basal forebrain cholinergic system: Relations to \u03b2-amyloid peptides, cognition, and treatment strategies","volume":"68","author":"Auld DS","year":"2002","unstructured":"Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer\u2019s disease and the basal forebrain cholinergic system: Relations to \u03b2-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 2002;68:209\u201345.","journal-title":"Prog Neurobiol"},{"year":"1979","author":"Whitehouse PJ","key":"ref8","unstructured":"Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer\u2019s disease and senile dementia: Loss of neurons in the basal forebrain. Science (1979). 1982;215:1237\u20139."},{"issue":"10","key":"ref9","article-title":"Mild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments","volume":"16","author":"Vega JN","year":"2014","unstructured":"Vega JN, Newhouse PA. Mild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments. Curr Psychiatry Rep. 2014;16(10).","journal-title":"Curr Psychiatry Rep"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase Inhibitors: Pharmacology and Toxicology","volume":"11","author":"Colovic MB","year":"2013","unstructured":"Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Curr Neuropharmacol. 2013;11:315\u201335.","journal-title":"Curr Neuropharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40266-015-0273-x","article-title":"The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer\u2019s Disease","volume":"32","author":"Deardorff WJ","year":"2015","unstructured":"Deardorff WJ, Feen E, Grossberg GT. The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer\u2019s Disease. Drugs Aging. 2015;32:537\u201347.","journal-title":"Drugs Aging"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/13543784.2016.1216972","article-title":"Old and new acetylcholinesterase inhibitors for Alzheimer\u2019s disease","volume":"25","author":"Galimberti D","year":"2016","unstructured":"Galimberti D, Scarpini E. Old and new acetylcholinesterase inhibitors for Alzheimer\u2019s disease. Expert Opin Investig Drugs. 2016;25(10):1181\u20137.","journal-title":"Expert Opin Investig Drugs"},{"key":"ref13","first-page":"183","article-title":"Activation of M 1 and M 4 muscarinic receptors as potential treatments for Alzheimer\u2019s disease and schizophrenia","volume":"10","author":"Foster DJ","year":"2014","unstructured":"Foster DJ, Choi DL, Jeffrey Conn P, Rook JM. Activation of M 1 and M 4 muscarinic receptors as potential treatments for Alzheimer\u2019s disease and schizophrenia. Neuropsychiatr Dis Treat. 2014;10:183\u201391.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.drudis.2013.09.005","article-title":"Allosteric modulation of the M1 muscarinic acetylcholine receptor: Improving cognition and a potential treatment for schizophrenia and Alzheimer\u2019s disease","volume":"18","author":"Melancon BJ","year":"2013","unstructured":"Melancon BJ, Tarr JC, Panarese JD, Wood MR, Lindsley CW. Allosteric modulation of the M1 muscarinic acetylcholine receptor: Improving cognition and a potential treatment for schizophrenia and Alzheimer\u2019s disease. Drug Discov Today. 2013;18:1185\u201399.","journal-title":"Drug Discov Today"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras SG","year":"2003","unstructured":"Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci. 2003;6:51\u20138.","journal-title":"Nat Neurosci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","article-title":"A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning","volume":"29","author":"Shirey JK","year":"2009","unstructured":"Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. 2009;29:14271\u201386.","journal-title":"J Neurosci"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.tips.2008.12.002","article-title":"Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders","volume":"30","author":"Conn PJ","year":"2009","unstructured":"Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci. 2009;30(3):148\u201355.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","article-title":"Cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease. A comparison of tolerability and pharmacology","volume":"19","author":"Nordberg A","year":"1998","unstructured":"Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease. A comparison of tolerability and pharmacology. Drug Saf. 1998;19(6):465\u201380.","journal-title":"Drug Saf"},{"year":"2024","author":"Torjesen I","key":"ref19","unstructured":"Torjesen I, Schizophrenia. US approves first new treatment in decades. BMJ [Internet]. 2024 Sep 30 [cited 2025 Jan 16];386:q2133. Available from: https:\/\/www.bmj.com\/content\/386\/bmj.q2133"},{"author":"Mills J","key":"ref20","doi-asserted-by":"publisher","unstructured":"Mills J. A New Antipsychotic for Schizophrenia: Xanomeline and Trospium (Cobenfy). Issues Ment Health Nurs [Internet]. 2024 [cited 2025 Jan 16];45:1364\u20137. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/01612840.2024.2427561","DOI":"10.1080\/01612840.2024.2427561"},{"issue":"10","key":"ref21","first-page":"9","article-title":"Advances in Drug Discovery and Development in Geriatric Psychiatry","volume":"20","author":"Conley AC","year":"2018","unstructured":"Conley AC, Newhouse PA. Advances in Drug Discovery and Development in Geriatric Psychiatry. Curr Psychiatry Rep. 2018;20(10):9.","journal-title":"Curr Psychiatry Rep"},{"issue":"9","key":"ref22","first-page":"692","article-title":"Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders","volume":"13","author":"Conn PJ","year":"2014","unstructured":"Conn PJ, Lindsley CW, Meiler J, Niswender CM. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Publishing Group. 2014;13(9):692\u2013708.","journal-title":"Nat Publishing Group"},{"author":"Poslunsey MS","key":"ref23","doi-asserted-by":"publisher","unstructured":"Poslunsey MS, Wood MR, Han C, Stauffer SR, Panarese JD, Melancon BJ et al. Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials. ACS Chem Neurosci [Internet]. 2024 [cited 2025 Jan 21];16:95\u2013107. Available from: https:\/\/pubs.acs.org\/doi\/full\/10.1021\/acschemneuro.4c00769","DOI":"10.1021\/acschemneuro.4c00769"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/npp.2015.189","article-title":"Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model","volume":"41","author":"Ghoshal A","year":"2016","unstructured":"Ghoshal A, Rook JM, Dickerson JW, Roop GN, Morrison RD, Jalan-Sakrikar N, et al. Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model. Neuropsychopharmacology. 2016;41:598\u2013610.","journal-title":"Neuropsychopharmacology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1021\/acschemneuro.5b00123","article-title":"Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice","volume":"6","author":"Gould RW","year":"2015","unstructured":"Gould RW, Dencker D, Grannan M, Bubser M, Zhan X, Wess J, et al. Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice. ACS Chem Neurosci. 2015;6:1683\u201395.","journal-title":"ACS Chem Neurosci"},{"year":"2003","author":"Omura GA","key":"ref26","unstructured":"Omura GA. Modified Fibonacci search. J Clin Oncol [Internet]. 2003 Aug 1 [cited 2025 Mar 8];21(16):3177\u20133177. Available from: https:\/\/europepmc.org\/article\/med\/12915613"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/arclin\/4.4.351","article-title":"Relative influence of subject variables and neurological parameters on neuropsychological performance of adult seizure patients","volume":"4","author":"Kupke T","year":"1989","unstructured":"Kupke T, Lewis R. Relative influence of subject variables and neurological parameters on neuropsychological performance of adult seizure patients. Arch Clin Neuropsychol. 1989;4(4):351\u201363.","journal-title":"Arch Clin Neuropsychol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/978-3-642-69659-6_4","article-title":"Psychological performance models as indicators of the effects of hypnotic drugs on sleep","volume":"1","author":"Hindmarch I","year":"1984","unstructured":"Hindmarch I. Psychological performance models as indicators of the effects of hypnotic drugs on sleep. Psychopharmacol Suppl. 1984;1:58\u201368.","journal-title":"Psychopharmacol Suppl"},{"key":"ref29","first-page":"175","article-title":"Conners\u2019 Continuous Performance Test II (CPT II V. 5)","volume":"29","author":"Conners CK","year":"2000","unstructured":"Conners CK, Staff MHS, Connelly V, Campbell S, MacLean M, Barnes J. Conners\u2019 Continuous Performance Test II (CPT II V. 5). Multi-Health Syst Inc. 2000;29:175\u201396.","journal-title":"Multi-Health Syst Inc"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00335558008248231","article-title":"Orienting of attention","volume":"32","author":"Posner MI","year":"1980","unstructured":"Posner MI. Orienting of attention. Q J Experimental Psychol. 1980;32(1):3\u201325.","journal-title":"Q J Experimental Psychol"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1162\/jocn.1997.9.4.462","article-title":"Verbal working memory load affects regional brain activation as measured by PET","volume":"9","author":"Jonides J","year":"1997","unstructured":"Jonides J, Schumacher EH, Smith EE, Lauber EJ, Awh E, Minoshima S, et al. Verbal working memory load affects regional brain activation as measured by PET. J Cogn Neurosci. 1997;9(4):462\u201375.","journal-title":"J Cogn Neurosci"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/brain\/awh177","article-title":"Cholinergic enhancement of frontal lobe activity in mild cognitive impairment","volume":"127","author":"Saykin AJ","year":"2004","unstructured":"Saykin AJ, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain. 2004;127:1574\u201383.","journal-title":"Brain"},{"issue":"November","key":"ref33","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1212\/WNL.24.11.1019","article-title":"Evaluating storage,retention, and retrieval in disordered memory and learning","volume":"24","author":"Buschke H","year":"1974","unstructured":"Buschke H, Fuld PA. Evaluating storage,retention, and retrieval in disordered memory and learning. Neurology. 1974;24(November):1019\u201325.","journal-title":"Neurology"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF01186911","article-title":"Spatial sampling and filtering of EEG with spline laplacians to estimate cortical potentials","volume":"8","author":"Srinivasan R","year":"1996","unstructured":"Srinivasan R, Nunez PL, Tucker DM, Silberstein RB, Cadusch PJ. Spatial sampling and filtering of EEG with spline laplacians to estimate cortical potentials. Brain Topogr. 1996;8(4):355\u201366.","journal-title":"Brain Topogr"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neurobiolaging.2013.07.024","article-title":"Event-related potential index of age-related differences in memory processes in adults with down syndrome","volume":"35","author":"Key AP","year":"2014","unstructured":"Key AP, Dykens EM. Event-related potential index of age-related differences in memory processes in adults with down syndrome. Neurobiol Aging. 2014;35(1):247\u201353.","journal-title":"Neurobiol Aging"},{"key":"ref36","first-page":"24","article-title":"P3a and P3b from typical auditory and visual stimuli","volume":"110","author":"Comerchero MD","year":"1999","unstructured":"Comerchero MD, Polich J. P3a and P3b from typical auditory and visual stimuli. 1999;110:24\u201330."},{"year":"2007","author":"Polich J","key":"ref37","unstructured":"Polich J. Updating P300: An integrative theory of P3a and P3b. Clinical Neurophysiology [Internet]. 2007;118(10):2128\u201348. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388245707001897"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1388-2457(99)00044-9","article-title":"The polar average reference effect: A bias in estimating the head surface integral in EEG recording","volume":"110","author":"Jungh\u00f6fer M","year":"1999","unstructured":"Jungh\u00f6fer M, Elbert T, Tucker DM, Braun C. The polar average reference effect: A bias in estimating the head surface integral in EEG recording. Clin Neurophysiol. 1999;110(6):1149\u201355.","journal-title":"Clin Neurophysiol"},{"issue":"7","key":"ref39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1109\/10.686789","article-title":"Spatial filtering and neocortical dynamics: Estimates of EEG coherence","volume":"45","author":"Srinivasan R","year":"1998","unstructured":"Srinivasan R, Nunez PL, Silberstein RB. Spatial filtering and neocortical dynamics: Estimates of EEG coherence. IEEE Trans Biomed Eng. 1998;45(7):814\u201326.","journal-title":"IEEE Trans Biomed Eng"},{"year":"2017","author":"Okour M","key":"ref40","unstructured":"Okour M, Brundage RC. Modeling Enterohepatic Circulation. Curr Pharmacol Rep [Internet]. 2017 Oct 1 [cited 2025 Feb 12];3(5):301\u201313. Available from: https:\/\/link.springer.com\/article\/10.1007\/s40495-017-0096-z"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.brainresrev.2004.08.006","article-title":"Unraveling the attentional functions of cortical cholinergic inputs: Interactions between signal-driven and cognitive modulation of signal detection","volume":"48","author":"Sarter M","year":"2005","unstructured":"Sarter M, Hasselmo ME, Bruno JP, Givens B. Unraveling the attentional functions of cortical cholinergic inputs: Interactions between signal-driven and cognitive modulation of signal detection. Brain Res Rev. 2005;48(1):98\u2013111.","journal-title":"Brain Res Rev"},{"year":"2005","author":"Yu AJ","key":"ref42","unstructured":"Yu AJ, Dayan P. Uncertainty, neuromodulation, and attention. Neuron [Internet]. 2005 May 19 [cited 2023 Dec 14];46(4):681\u201392. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15944135\/"},{"year":"2002","author":"Yu AJ","key":"ref43","unstructured":"Yu AJ, Dayan P. Acetylcholine in cortical inference. Neural Netw [Internet]. 2002 Jun [cited 2023 Dec 14];15(4\u20136):719\u201330. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12371522\/"},{"author":"Levey AI","key":"ref44","unstructured":"Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci [Internet]. 1993 [cited 2022 Mar 14];52(5\u20136):441\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8441326\/"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1523\/JNEUROSCI.15-05-04077.1995","article-title":"Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation","volume":"15","author":"Levey AI","year":"1995","unstructured":"Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci. 1995;15:4077\u201392.","journal-title":"J Neurosci"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1523\/JNEUROSCI.11-10-03218.1991","article-title":"Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies","volume":"11","author":"Levey AI","year":"1991","unstructured":"Levey AI, Kitt Ca, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci. 1991;11(10):3218\u201326.","journal-title":"J Neurosci"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.226712","author":"Lange HS","year":"2015","unstructured":"Lange HS, Cannon CE, Drott JT, Kuduk SD, Uslaner JM. The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics [Internet]. 2015;355(3):442\u201350. Available from: http:\/\/jpet.aspetjournals.org\/cgi\/doi\/10.1124\/jpet.115.226712"},{"issue":"11","key":"ref48","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00213-014-3813-x","article-title":"Improved cognition without adverse effects: Novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey","volume":"232","author":"Vardigan JD","year":"2015","unstructured":"Vardigan JD, Cannon CE, Puri V, Dancho M, Koser A, Wittmann M, et al. Improved cognition without adverse effects: Novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. Psychopharmacology. 2015;232(11):1859\u201366.","journal-title":"Psychopharmacology"},{"issue":"9","key":"ref49","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1021\/acschemneuro.8b00131","article-title":"A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity","volume":"19","author":"Rook JM","year":"2018","unstructured":"Rook JM, Bertron JL, Cho HP, Garcia-Barrantes PM, Moran SP, Maksymetz JT, et al. A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity. ACS Chem Neurosci. 2018;19(9):2274\u201385.","journal-title":"ACS Chem Neurosci"},{"author":"Moran SP","key":"ref50","unstructured":"Moran SP, Dickerson JW, Cho HP, Xiang Z, Maksymetz J, Remke DH et al. M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition. Neuropsychopharmacology [Internet]. 2018 Jul 14 [cited 2018 Jul 4];43(8):1763\u201371. Available from: http:\/\/www.nature.com\/articles\/s41386-018-0033-9"},{"year":"2025","author":"Shanbhag NM","key":"ref51","unstructured":"Shanbhag NM, Padmanabhan JL, Zhang Z, Harel BT, Jia H, Kangarloo T et al. An Acetylcholine M1 Receptor\u2013Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial. JAMA Neurol [Internet]. 2025 Jan 6 [cited 2025 Jan 16]; Available from: https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2828334"},{"author":"Olichney JM","key":"ref52","unstructured":"Olichney JM, Hillert DG. Clinical applications of cognitive event-related potentials in Alzheimer\u2019s disease. Physical Medicine and Rehabilitation Clinics [Internet]. 2004 Feb 1 [cited 2025 Jan 21];15(1):205\u201333. Available from: http:\/\/www.pmr.theclinics.com\/article\/S1047965103001037\/fulltext"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.12659\/MSM.894940","article-title":"Distinctive effect of donepezil treatment on P300 and N200 subcomponents of auditory event-related evoked potentials in Alzheimer disease patients","volume":"21","author":"Vaitkevi\u010dius A","year":"2015","unstructured":"Vaitkevi\u010dius A, Kaubrys G, Audronyt\u0117 E. Distinctive effect of donepezil treatment on P300 and N200 subcomponents of auditory event-related evoked potentials in Alzheimer disease patients. Med Sci Monit. 2015;21:1920\u20137.","journal-title":"Med Sci Monit"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1550059414550567","article-title":"P300 Amplitude in Alzheimer\u2019s Disease","volume":"47","author":"Hedges D","year":"2016","unstructured":"Hedges D, Janis R, Mickelson S, Keith C, Bennett DAVID, Brown BL. P300 Amplitude in Alzheimer\u2019s Disease. Clin EEG Neurosci. 2016;47(1):48\u201355.","journal-title":"Clin EEG Neurosci"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000054957","article-title":"Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer\u2019s disease","volume":"45","author":"Knott V","year":"2002","unstructured":"Knott V, Mohr E, Mahoney C, Engeland C, Ilivitsky V. Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer\u2019s disease. Neuropsychobiology. 2002;45:156\u201360.","journal-title":"Neuropsychobiology"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pbb.2014.03.020","article-title":"Baseline-dependent modulating effects of nicotine on voluntary and involuntary attention measured with brain event-related P3 potentials","volume":"122","author":"Knott V","year":"2014","unstructured":"Knott V, Choueiry J, Dort H, Smith D, Impey D, De La Salle S, et al. Baseline-dependent modulating effects of nicotine on voluntary and involuntary attention measured with brain event-related P3 potentials. Pharmacol Biochem Behav. 2014;122:107\u201317.","journal-title":"Pharmacol Biochem Behav"},{"year":"1989","author":"Meador KJ","key":"ref57","unstructured":"Meador KJ, Loring DW, Davis HC, Sethi KD, Patel BR, Adams RJ et al. Cholinergic and serotonergic effects on the P3 potential and recent memory. J Clin Exp Neuropsychol [Internet]. 1989 [cited 2025 Jan 21];11(2):252\u201360. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/01688638908400887"},{"key":"ref58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris PA","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95.","journal-title":"J Biomed Inf"},{"issue":"2","key":"ref59","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris PA","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381.","journal-title":"J Biomed Inf"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6271510\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6271510\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T16:18:47Z","timestamp":1751905127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6271510\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":59,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6271510\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s13195-025-01798-4","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,4,4]]},"subtype":"preprint"}}